LATEST NEWS
EXACT Therapeutics announces first half 2023 interim results
EXACT Therapeutics announces appointment of Caspar Foghsgaard as SVP Commercial & Business Development
EXACT Therapeutics announces positive clinical results from the ACTIVATE Phase I dose escalation
Invitation to first half results 2023 presentation of EXACT Therapeutics AS
Wall Street Journal:
New Ultrasound Therapy Could Help Treat Alzheimer’s, Cancer